19^th Global Biomarkers and Clinical Research Summit

National Institute of Standards and Technology, Project Leader/Biologist, Division of Biomedical Sciences, USA

Biomarkers

Youhe Gao Professor Beijing Normal University. He received his MD from Peking Union Medical College, his Ph.D. from the University of Connecticut, and postdoctoral training from Beth Israel Deaconess Medical Center, Harvard Medical School. He was the professor of the Department of Pathophysiology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences/ Peking Union Medical College from 2001-2014. His research interests include biomarker discovery in urine, urine biobanking, protein interaction methods, and related bioinformatics.

His research interests include biomarker discovery in urine, urine biobanking, protein interaction methods, and related bioinformatics.

Vice Head of Pediatric Department Haiphong Children Hospital Vietnam

biomarkers

Wuhan University China

Biomarkers

"Associate Professor, Department of Urology Osaka City University Graduate School of Medicine, Japan"

Biomarkers

"Associate Professor, Departments of Public Health and Cardiovascular Sciences East Carolina University, USA"

Biomarkers

"Professor, Department of Immunology/Biochemistry/Oncology Witten-Herdecke University, Germany"

Biomarkers

Analytical Scientist, NIAID/NIH, USA

Biomarkers

"Professor, Department of Molecular and Cellular Oncology University of Texas, USA"

Biomarkers

"Professor and Chair, Department of Neurology Wayne State University, USA"

Biomarkers

Keio University School of Medicine, Assistant ProfessorDivision of Nephrology, Endocrinology and Metabolism, Japan

Biomarkers

"Executive Editor Department of Biochemistry and Molecular Biology University of Nebraska Medical Center, College of Medicine, USA"

Biomarkers

Claudio Nicolini was born in Udine, Italy. He received the doctoral degree in physics from the University of Padua, in 1967. After serving as Adjunct Professor at the University of Bari, he moved for 17 years to the United States, of which he became citizen since 1974, and was originally at Brown University, MIT, and BNL. He then moved to Temple University School of Medicine, Philadelphia, where after a period of intensive training and research in pathology he became Associate Professor of Pathology and then Professor and Chairman of the Biophysics in 1976. In 1985, he was called as “eminent scientist” to the Chair of Biophysics of the University of Genoa, in Italy until 2012, where he was successively Director of Biophysics Institute, DISTBIMO and CIRSDNNOB. From 1993 until now is Life President of the Fondazione ELBA Nicolini and of the Nanoworld Institute. On 2008 has been elected as a Foreign Member of the Russian Academy of Sciences and on 2010 Honoris Causa Professor of Biophysics and Nanobiotechnology at Moscow State University. He was Chief Editor of Cell Biophysics (USA), Science and Technology Advisor to Italian Prime Minister Craxi, Member of the National Science and Technology Council upon Parliament election, Scientific Director Industrial Consortium CIREF, Founder Technobiochip; President Polo National Bioelectronics, President Scientific Technological Park of Elba Island. He received several awards and prizes and has authored more than 480 publications in international scientific journals (SCI), 35 patents (WPI), 28 books and Series Editor in Bioelectronics (Plenum) and Nanobiotechnology (Pan Stanford). His main scientific activities concerned cancer research, biophysics and nanotechnology, pioneering world-wide chromatin structure-function, bioelectronics and nanobiotechnology.

Cancer research, Biophysics and Nanotechnology, pioneering world-wide chromatin structure-function, Bioelectronics and Nanobiotechnology.

Dr. Alain Moreau is Full Professor in the Faculty of Dentistry and the Faculty of Medicine at the Universite de Montreal. He is the Director of Research and Chief Scientific Officer of Sainte-Justine University Hospital.Dr. Moreau received his PhD in Microbiology and Immunology from the Universite de Montreal in 1993. He did a first postdoctoral training at the Protein Engineering Center of University of Liege, Belgium (1992-1993), followed by a second postdoctoral fellowship at the Shriners Hospital for Children in Montreal affiliated with McGill University (1993-1997). Dr. Moreau is an internationally recognized expert on molecular genetics of pediatric scoliosis and osteoarthritis. His discoveries led to multiple peer-reviewed papers, international conferences as guest speaker, several awards as well as 32 patents issued.

Protein engineering, Molecular genetics, Biomarkers

Chee Gee See is the Director of Personalised Medicine at Proteome Sciences, a company providing high end mass-spectrometry based biomarker discovery and clinical utility tools, uniquely positioned to engage with pharma partners in our quest for personalised medicines. CheeGee was previously the clinical Biomarker and Experimental Medicine Leader at Roche for 5 years. He was the BEML for the Phase III pivotal TOGA study where Herceptin was trialled for the new indication of gastric cancer. He was also a BEML for CVD, CNS and immunology so his range and awareness of disease areas and their clinical development challenges is both deep and broad. CheeGee also spent 11 years at GSK where he was a genetics expert covering 3 key therapeutic areas in preclinical research within Genetics Research Europe. Prior to industry, CheeGee spent 6 years in post-doctoral academia at the University of Birmingham and University College London, most notably in the Human Genome Mapping Project. CheeGee also has dual specialist expertise as a consultant in regulatory affairs and value-based drug pricing, reimbursement and market access. CheeGee looks forward to engaging with like-minded professionals during this conference.

Personalised Medicine, biomarkers, genetics

B.Sc and M.Sc. degrees from Allahabad University and Ph.D. from Gujarat University. Areas of Specialization: Life Sciences, Radiation Biology, Biotechnology, Biophysics and chemistry. Research Guide for Ph.D. students in many Universities of India. Successfully guided 41 Ph.D. students. Presently guiding 08 students. Published more than 280 research papers and proceeding papers in National and International Journals. Delivered more than 300 invited talks in Symposia and Conferences. Currently the Vice Chancellor of Nehru Gram Bharati University, Allahabad, India. Served as Head, Radiation Biology and Health Science Division and Senior Scientific Officer of Bhabha Atomic Research Center, Department of Atomic Energy, and Government of India. Chairman, Standing Selection Committee, Member, Trombay Scientific Council, BARC, Member, Health, Safety & Biomedical Group Board, Member, Committee of Atomic Energy Commission on Health and Environment Aspects of Uranium Mining at Jaduguda, Member, Core Expert Group on Chemical Disaster and Nuclear Disaster Management of National Disaster Management Authotrity of India (NDMA). Served as Chancellor's Nominee in Selection Committees of Padmashri Dr. D.Y. Patil Deemed University; Mumbai and West Bengal University of Technology, Kolkata and served as Expert on Selection Committees of IITs and several Universities in India.

Radiation Research, Biomarkers, Biophysics, Biotechnology

Leticia Cano identified a native citrullinated autoantigen for rheumatoid arthritis for her PhD dissertation. She did her postdoctoral training in the laboratory of Hank Fales at the National Institutes of Health, where she identified candidate biomarkers for Dermatomyositis, Juvenile Idiopathic Arthritis, and Systemic Lupus Erythematosus. As founder and president of Biomarker Profiles Corporation, she is interested in developing methods to increase the speed of biomarker discovery.

Biomarkers

Pavel Vodicka graduated at the Medical Faculty, Charles University, Prague and in 1986 obtained PhD in biochemistry. He worked as postdoctoral fellow at the Finnish Inst. Occupat. Health, Helsinki, Finland (1987-1990) and as visiting scientist at Karolinska Institute, Huddinge, Sweden (1990-1993). Since 2002 he heads the Dept. Molec. Biol. Cancer, Inst. Exper. Medicine, Acad. Sci., Prague, Czech Republic. Pavel Vodicka has published more than 130 (total IF 552.4, 2650 citations a HI 31) articles. Since 2004, his main research topics are focused on the DNA and chromosomal damage and DNA repair functional tests in humans and on transient biomarkers in the onset of gastrointestinal cancers. In 2012 he edited the Special Issue in Mutagenesis http://mutage.oxfordjournals.org/content/27/2.toc), entitled Colorectal Cancer-Current Insights into Susceptibility.

Biochemistry, Molecular biology, biomarkers, cancer biology

Sergey Suchkov graduated from Astrakhan State Medical University and was awarded with MD. In 1985, Suchkov obtained his Ph.D. He is the PhD student of the I.M. Sechenov Moscow Medical Academy and Institute of Medical Enzymology, USSR Academy of Medical Sciences, Moscow, Russia. In 2001, Suchkov finished the PostDoc Research Fellowship Program and maintained his Doctor Degree at the National Institute of Immunology, Russia. From 1987 through 1989, Dr. Suchkov was a senior Researcher, Lab of Developmental Immunology, Koltzov Institute of Developmental Biology, USSR Academy of Sciences to deal to developmental immunology. From 1989 through 1995, Dr. Suchkov was being a Head of the Lab of Clinical Immunology and Immunobiotechnology, Helmholtz Eye Research Institute in Moscow. From 1995 through 2004, Dr. Suchkov was being a Chairman of the Department for Clinical Immunology, Moscow Clinical Research Institute (MONIKI) and the Immunologist-in-Chief of the Moscow Regional Ministry of Health. At present, Dr Sergey Suchkov, MD, PhD, is Professor in Immunology, Department of Pathology, School for Pharmacy, I.M. Sechenov First Moscow State Medical University, Dean of the Department (Faculty) of The PPPM Development, and the First Vice-President of the University of World Business, Politics and Law and Secretary General, United Cultural Convention (UCC), Cambridge, UK.

Enzymology, biomarkers, cardiology, Immunology

Gabriella Baio studied Medicine and Surgery at University of Pisa and she obtained Radiology specialization at University of Genoa in 2007. Since 2008, she works as Radiologist at IRCCS Azienda Ospedaliera Universitaria San Martino-IST-National Cancer Institute, in Genoa. Dott. Baio research activities, cover clinical and preclinical molecular imaging by Magnetic Resonance and Optical Imaging applied to oncology, vascular and neuroscience. Her current research consist in the characterization of breast cancer in animal model, in order to validate new contrast agents as potential biomarkers for early diagnosis and drug delivery. She is invited speaker to national and international conferences and an active member of the European Society of Molecular Imaging (ESMI). She has been abstract reviewer for the World Molecular Imaging Congress (WMIC) 2011 and 2012.

Radiology

Tao Chen has completed his Ph.D. from University of Arkansas for Medical Sciences, diplomat of the American Board of Toxicology and postdoctoral studies from Duke University. He has been a Principal Investigator in National Center for Toxicological Research since 2010 and is also an Adjunct Professor in two universities. He has served as an editorial board member and reviewer in a number of journals, a consultant for the World Health Organization, a reviewer for research proposals for US National Science Foundation. He has published more than 200 manuscripts and abstracts in peer-reviewed journals and books, and scientific meetings.

He has been a Principal Investigator in National Center for Toxicological Research

Lori A. Henderson is a Program Director at the National Institute of Biomedical Imaging and Bioengineering (NIBIB), an institute at the National Institutes of Health (NIH), and has 17 years experience with technical and managerial expertise in several scientific areas: bioengineering, biotechnology, materials science, nanotechnology, enzymology, and biomedical technologies. She currently manages the Nanotechnology and Drug and Gene Delivery programs within the Division of Discovery Science and Technology in the Extramural Division of the NIBIB. She also represents the NIH on the National Science and Technology Council (NSTC) subcommittee on Nanoscale Science, Engineering & Technology (NSET). Her responsibilities at the NIH also include co-managing projects within the Nanomedicine, Interdisciplinary Research, and Regulatory Science programs supported by the NIH Common Fund. These trans-NIH and trans-agency programs include research projects that cut across scientific disciplines and challenges conventional thinking. Prior to the NIH, Dr. Henderson was a Group Leader of the Biomaterials Group within the Polymers Division at the National Institute of Standards and Technology (NIST). Before joining NIST in 2005, Dr. Henderson worked for Novozymes North America, BASF, and Akzo Nobel, where she was a research supervisor, global project leader, and a senior scientist. Dr. Henderson holds a M.S. degree in Macromolecular and Organic Chemistry, and obtained a Ph.D. in Polymer Science from University of Massachusetts, Lowell.

Clinical Trials Branch/Cancer Imaging Program

Alan Prem Kumar earned his Ph.D. from University of North Texas, USA. From his Ph.D. work, he discovered a novel regulatory protein, PyrR for the pyrimidine biosynthetic pathway in Pseudomonas. Dr. Kumar then pursued Postdoctoral training in Cancer Research at Sidney Kimmel Cancer Center, California, USA. He was awarded a Postdoctoral Fellowship for his work on the role of nuclear receptors. Dr. Kumar relocated back to Singapore to join Cancer Science Institute of Singapore, National University of Singapore as an independent Principal Investigator to continue on his expertise on nuclear receptor and cancer pharmacology. His current research interest includes the role of nuclear receptors involved in the regulation of target genes and to elucidate mechanism and associated signal pathways. Another area of interest is aimed at developing new derivative drugs with hopefully fewer side effects. Over the years, Dr. Kumar and his laboratory have forged relationships with scientists in cancer research and with cancer advocacy groups in Singapore.

My primary research focuses in the areas of signaling by nuclear receptors and oncogenes as well as the development of molecular therapeutics and biomarkers of drug action in human breast cancer. We recently identified a novel oncogene that regulates a key pathway controlling cell proliferation, migration and drug resistance in breast, prostate, gastric, and colon cancers. Current research also focuses on developing therapeutic strategies to target this marker with the ultimate aim of conducting translational studies in patients.

Research and Working experience: March 2011-date as Assistant Research Professor, Biosample Repository Facility, Fox Chase Cancer Center, Philadelphia. Jan 2006-Dec 2010 as Instructor, Department of Pathology and Laboratory Medicine, UMDNJ-Robert Wood Johnson Medical School, New Jersey. March 2002 - Jan 2006 as Research Associate, Fox Chase Cancer Center, Philadelphia. Aug 2000 - Feb 2002 as Postdoc Associate, Fox Chase Cancer Center, Philadelphia. Apr 1997 - July 2000 Faculty member (instructor), Department of Anatomy and Cell Biology, Kagoshima University Faculty of Medicine, Japan. Aug 1990 - Jan 1993 Microbiology Inspector, Import and Export Commodities Inspection Bureau, GuangZhou, China.

Immunohistochemistry (IHC) for both basic and clinical research, Gene regulation on embryogenesis, organogenesis, tumorigenesis and multi-drug resistance, automatic quantitative analysis (AQUA) on both basic and clinical research, particularly in biomarker characterization and discovery, Ovarian cancer biology, understanding the molecular alterations of known and novel signaling pathways that regulate embryogenesis, organ morphogenesis, preneoplastic transformation and tumorigenicity

Neil Box is a Assistant Professor in the Department of Dermatology at the University of Colorado Denver. He is a member of the University of Colorado Cancer Center, Skin Diseases Research Center and the Charles C. Gates Regenerative Medicine and Stem Cell Biology Center. He is an active member of the Skin Cancer Tissue Bank executive committee. He has received Research Career Development Awards from the Dermatology Foundation and the American Skin Association. Dr. Box completed his graduate school training on the genetics of human hair, skin and eye color in the laboratory of Dr. Richard Sturm at the University of Queensland, Australia. During this period he identified some of the key red hair color variants at the MC1R locus (eg. R151C, R160W). His subsequent research on this subject produced some of the seminal melanoma association and gene interaction studies for MC1R. Since moving to the USA in 2001, he performed postdoctoral trained with two leading scientists in mouse models of human disease: Dr. Monica Justice and Dr. Dennis Roop at Baylor College of Medicine. From this work, he has assembled a research program aimed at uncovering the molecular mechanisms regulating melanoma risk. Since his recruitment to the University of Colorado in 2007, he has also continued his interests in working with human melanoma risk genes to explore their potential clinical and public health applications.

The mouse as a model for human melanocyte and melanoma development.

Yuxun Wang is currently the Executive Director and Head of Cancer Biology at HD Biosciences. He has a blend of experiences in both academia and biopharmaceutical industry in the US. Previously, he was associate director at Metamark Genetics, assistant professor at University of South Carolina and senior scientist at Merck Research Laboratory. His research has focused on translational oncology, cancer drug and predictive biomarker discovery. He has over 24 research publications and patent, numerous conference presentations and invited talks. He has received a number of awards recognizing his research and service in both academia and industry.

Head of Cancer Biology at HD Biosciences. He has a blend of experiences in both academia and biopharmaceutical industry in the US

Geetika Chakravarty's research is geared towards the identification and evaluation of new cancer stem cell biomarkers and novel strategies to target them using breast cancer as the model system. Her research has resulted in patents, invited book chapter and several first and co-authored publications. She is also dedicated to help maintain the most rigorous standards of scientific inquiry and progress and as such serves as the editorial board member and journal reviewer of cancer related journals.

Her research is geared towards the identification and evaluation of new cancer stem cell biomarkers and novel strategies to target them using breast cancer as the model system. Her research has resulted in patents,

Sevtap Savas obtained her Ph.D. in Molecular Biology and Genetics in 1999. She was trained as a post-doctoral trainee and a Research Associate at Louisiana State University (USA), Mount Sinai Hospital Research Institute (Canada) and Princess Margaret Hospital/Ontario Cancer Institute (Canada), before joining the Memorial University (Canada) as an Assistant Professor in 2008. She has a multidisciplinary research program integrating molecular genetics, bioinformatics, biostatistics and epidemiology and currently focuses on identification of genetic markers that can predict clinical outcome in colorectal cancer patients.

Role of genetic variation in cancer susceptibility; Role of genetic variation in treatment response (pharmacogenetic), Role of genetic variation in clinical outcomes and survivorship in cancer; Role of somatic mutations in cancer predisposition treatment response and clinical outcome; Role of mitochondrial genome in cancer predisposition, treatment response and clinical outcome; Bioinformatics application and establishment of biological databases, High-throughput genotyping technologies and resequencing studies

Yaguang Xi got the Ph.D from Peking University after his clinical training. He is an Assistant Professor at the University of South Alabama Mitchell Cancer Institute. To date, Dr. Xi has authored 43 publications in many prestigious journals and is serving as the member of editorial board and ad-hoc reviewer for many journals and grant agencies.

Discovery and validation of novel biomarkers associated with tumor progression, metastasis, therapeutic response and chemoprevention,

Michael Holinstat is an assistant professor of Medicine at Thomas Jefferson University in Philadelphia. He received his Ph.D. in Pharmacology from the University of Illinois at Chicago and postdoctoral training at Vanderbilt University in the Department of Pharmacology. His research focuses on identifying novel approaches to anti-platelet therapy with a special emphasis on regulation of platelets through the lipoxygenase pathway leading to a number of oxidized fatty acids which may play a central role in regulating unwanted platelet activation. Additionally, the lab studies regulation of platelet signaling through PAR1 and PAR4.

Thrombosis; Rap1; Gpcr; Signal Transduction; Platelet; Pharmacology; Hematology; Medicine; Small G Protein; Signal Transduction; Signaling; Lipoxygenase; 12-Lipoxygenase; 12-HETE; 12-HETrE.

Feng Yan, has completed her Ph.D from Yangzhou University in China. She is the Vice Director of Department of Clinical Laboratory in Jiangsu Cancer Hospital, and an Professor of Nanjing Medical University. The research works of Feng Yan focus on the bioanalytical chemistry in laboratory medical diagnostics, particularly in detection of tumor markers and tumor cells. She was the Outstanding Medical Talents (2007), Excellent Medical Talent (2011) and Leading Medical Talent (2011) of Jiangsu Province. She has published more than 42 papers in reputed journals.

The research works of Feng Yan focus on the bioanalytical chemistry in laboratory medical diagnostics, particularly in detection of tumor markers and tumor cells.

Jamal Zweit is a Professor of Radiology, Radiation Oncology, Molecular Pathology, and Biochemistry & Molecular Biology. He is also the Director of the Center for Molecular Imaging at Virginia Commonwealth University Medical Center. He leads an inter-disciplinary and inter-collaborative molecular imaging research program that emphasizes multi-modality approaches to study biochemical and biological pathways in vivo. Professor Zweit's research interests include the development of paradigms for molecular imaging and nanotechnology strategies for preclinical and clinical translational research in cancer biology and therapeutics. He is internationally recognized for his work in molecular imaging of cancer drug development, and conducted the "world’s first" Molecular PET Imaging clinical trial of Anti-angiogenic therapy in cancer patients (Journal National Cancer Institute 2002). Professor Zweit serves as an advisor on a number of committees, including the Cancer Research UK Pharmacodynamic and Pharmacokiunetic Technologies Advisory Committee (Journal National Cancer Institute, 2006). He serves on the review body of a number of funding organizations, both in Europe and North America. He has supervised a total of 24 MSc, MD and PhD theses. He has published more than 100 peer reviewed articles, over 250 conference abstracts, and 6 review articles and book chapters. Professor Zweit obtained his PhD and DSc from the University of Manchester Medical School. Prior to that, He studied for an MSc degree in PET Pharmacology. He received his Nuclear Medicine training at the John F. Kennedy Medical Centre in New Jersey, and attended advanced Nuclear Medicine training at the Brooklyn Hospital in New York As an Undergraduate, he obtained his Bachelor of Science degree, in Radiation Biophysics, with a Biochemistry double major, from the University of Kansas.

Multi-modality molecular and cellular imaging. Biologically targeted probe development and ulti-probe pre-clinical imaging. Nano-particle and quantum dot molecular and cellular imaging. Translational clinical molecular imaging in drug development. Pharmacokinetics and pharmacodynamics studies in oncology and neuroscience.

Dr. Bowser is Chairman of Neurobiology and Director of the Gregory W. Fulton ALS and Neuromuscular Research Center at the Barrow Neurological Institute and St. Joseph's Hospital and Medical Center in Phoenix, AZ. He obtained his PhD from Yale University School of Medicine and was a faculty member at the University of Pittsburgh School of Medicine for 18 years prior to his arrival in Phoenix in 2011. Dr. Bowser is also co-Founder of Knopp Biosciences, LLC and Iron Horse Diagnostics, Inc., biotechnology companies advancing new treatments and ways to diagnose neurologic disorders. Iron Horse Diagnostics is commercializing the first diagnostic test for ALS. Dr. Bowser's research interests are to determine the molecular and cellular basis of motor neuron cell death in ALS and translate these findings to the clinic. His laboratory leads efforts in the discovery and validation of protein biomarkers for ALS. Dr. Bowser also pursues methods to monitor ALS disease progression and drug effects during clinical trials. He has national and international leadership positions in the field of ALS, and co-Chairs a national ALS Biorepository, providing biofluid and tissue samples collected using standardized procedures to ALS investigators throughout the country.

Dr. Bowser's research interests are to determine the molecular and cellular basis of motor neuron cell death in ALS and translate these findings to the clinic. His laboratory leads efforts in the discovery and validation of protein biomarkers for ALS. Dr. Bowser also pursues methods to monitor ALS disease progression and drug effects during clinical trials. He has national and international leadership positions in the field of ALS, and co-Chairs a national ALS Biorepository, providing biofluid and tissue samples collected using standardized procedures to ALS investigators throughout the country.

Jagat Kanwar is an Immunologist and Molecular Biochemist. He is group leader of the Laboratory of Immunology and Molecular Biomedical Research. Kanwar's research work generated in total of 12 patent/PCTs with two provisionals in preparation. Five of these patents have been licensed for commercialization to biotech companies Antisoma, NeuronZ, Neuren Pharmaceuticals and Fonterra. He was invited as a speaker in more than 30 conferences and chaired sessions in Immunology, Nanotechnology, Nanomedicine and Biotechnology.

Nanomedicine, multi-targeted oral or intravenous delivery systems, nano-medicinal based vaccines and immunotherapy, micro-fluidics and lab-on-a-chip devices.

Assistant Professor & Director MEBRL, Division of Epidemiology, 1990-Present, School of Public Health, University of Minnesota Minneapolis, MN Research Associate, Division of Epidemiology, 1987-1990, School of Public Health, University of Minnesota, Minneapolis, MN Research Fellowship, National Research Service Award, 1984-1987 Endocrine Research Unit, Mayo Clinic, Rochester, MN Dr. Gross is Director of the Molecular Epidemiology and Biomarker Research Laboratory at the University of Minnesota. He has overseen analysis for numerous epidemiologic projects and has published extensively in the areas of antioxidants and oxidative damage. His experience includes serving as principal investigator of the laboratory core for the University of Minnesota CPRU program project, co-principal investigator of YALTA and as co-investigator of several clinical trials and epidemiologic studies emphasizing diet, genetics and biological markers. His laboratory has served as an analytical facility for several multicenter studies including CARDIA, ARIC and CATCH. Sample tracking, data handling, biochemical analysis and sample storage for large epidemiologic studies are a routine part of his laboratory.

Biomarker development/translational research, molecular/biochemical epidemiology, antioxidants, oxidative damage and risk of cardiovascular disease, DNA repair and genetic susceptibility in the risk of breast cancer, early detection of pancreatic prostate cancer, dietary and genetic factors in Alzheimer’s and successful aging